A Pioglitazone Nanoformulation Designed for Cancer-Associated Fibroblast Reprogramming and Cancer Treatment

Area of Science:

• Oncology
• Nanomedicine
• Biomaterials

Background:

• The tumor microenvironment (TME) often suppresses anti-cancer immune responses, hindering therapeutic effectiveness.
• Cancer-associated fibroblasts (CAFs) within the TME create a barrier, promoting tumor progression and drug resistance.
• Reprogramming CAFs to a less immunosuppressive state is a key strategy to improve cancer therapy outcomes.

Purpose of the Study:

• To design and evaluate a novel nanoformulation for reprogramming CAFs in breast cancer.
• To investigate the efficacy of pioglitazone delivered via nanoparticles for CAF modulation.
• To assess the impact of this approach on therapeutic drug penetration and tumor growth inhibition.

Main Methods:

• Development of glutathione (GSH)-responsive dendritic mesoporous organosilica nanoparticles loaded with pioglitazone (DMON-P).
• DMON-P was designed for targeted delivery to the GSH-rich cytosol of CAFs within the breast cancer TME.
• Evaluation of DMON-P's ability to reprogram CAFs, enhance doxorubicin (Dox) penetration, and inhibit tumor growth in preclinical models.

Main Results:

• DMON-P successfully delivered pioglitazone to CAFs, mediating their reprogramming.
• The nanoformulation enhanced the penetration of doxorubicin (Dox) into the tumor.
• Treatment with DMON-P led to the downregulation of CAF biomarkers and significant inhibition of tumor growth.

Conclusions:

• Pioglitazone-loaded nanoparticles offer a promising strategy for reprogramming CAFs in the breast cancer TME.
• This approach can overcome therapeutic barriers posed by CAFs, enhancing drug delivery and efficacy.
• DMON-P represents a novel therapeutic avenue for improving outcomes in CAF-rich tumors, particularly breast cancer.